UPCOMING SESSIONS in ET
Wed, Apr 29, 2026
10:00 – 11:00 PM UTC
ATTR-CM how do I know my treatment is working? Rebecca Hung MD Click To Register
UPCOMING SESSIONS in ET
Wed, Apr 29, 2026 · 10:00 – 11:00 PM UTC
ATTR-CM how do I know my treatment is working?
Rebecca Hung MD
Click To Register
View all sessions

Phase III

Logo_Alnylam_460-1.png
Alnylam Reports Positive Topline 18-Month Results From HELIOS-A Phase 3 Study of Vutrisiran in Patients With hATTR Amyloidosis With Polyneuropathy
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi…
Read more
alnylam.png
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3…
Read more
eidos_therapeutics_attribute-cm.jpg
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
Eidos Therapeutics, Inc., today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with Transthyretin (TTR)…
Read more
Ray Comenzo, MD, Discusses ANDROMEDA Trial in AL Amyloidosis Patients
The ANDROMEDA trial is a trial that is extremely important for patients who have systemic light chain or AL-amyloidosis. I'd like to begin by thanking Janssen…
Read more
Subscribe to